Navigation Links
Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
Date:1/31/2008

WALTHAM, Mass., Jan. 31 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a leading manufacturer and marketer of rapid diagnostic products for the consumer and professional markets, announced today that it will attend the upcoming 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference being held February 5 through 7, 2008 at the Grand Hotel Hyatt in New York City. Ron Zwanziger, Chief Executive Officer, and Jon Russell, Vice President, Finance, will attend. Their presentation is scheduled for Tuesday, February 5, 2008 at 8:40 p.m., and will be made available to the public through a webcast accessible through the company's website at http://www.invmed.com/investors.cfm and through Merrill Lynch's website at http://www.veracast.com/webcasts/ml/globalpharma08/81102144.cfm. https://events.jpmorgan.com/ A replay of the webcast will be available via the links above for approximately 3 months from the date of the webcast. During his presentation Mr. Zwanziger and Mr. Russell may discuss and answer questions concerning business and financial developments and trends. His responses to questions, as well as other matters discussed during the webcast, may contain or constitute information that has not been disclosed previously.

Prior to the conference Inverness will also be posting an updated investor presentation to its website at http://www.invmed.com/presentations.cfm.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
9. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
10. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
11. BioMS Medical announces its intention to renew a normal course issuer bid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Malden, MA (PRWEB) , ... March 23, 2017 ... ... as, “a viscoelastic material that exhibits both viscous and elastic characteristics when deformed, ... AxioMed disc polymer exhibits properties to gently absorb compressive forces and return to ...
(Date:3/23/2017)... 23, 2017 Research and Markets has ... report to their offering. ... The Global Market for Bioproducts ... 2016 at a CAGR of 8.9%, This ... bioproducts into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
Breaking Biology Technology:
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):